Author(s):
Harshal S Patil, Sourabh Jain, Karunakar Shukla, Paresh A Patil
Email(s):
Email ID Not Available
DOI:
10.52711/0975-4377.2022.00021 
Address:
Harshal S Patil1, Sourabh Jain1, Karunakar Shukla1, Paresh A Patil2
1College of Pharmacy, Dr. APJ Abdul Kalam University, Indore, M.P.
2Ahinsa Institute of Pharmacy, Dondaicha.
*Corresponding Author
Published In:
Volume - 14,
Issue - 2,
Year - 2022
ABSTRACT:
The fundamentals ?f a successful pharmaceutical f?rmulati?n depend ?n the delivery ?f the medicament t? the target site at therapeutically relevant level, with negligible ?r minimum disc?mf?rt and side effects t? the patient. Low dose maintenance therapy of Piperine HCl has the capability to reduce potential side effects and improved patient compliance which are more common with conventional drug delivery. The developed formulation of Piperine HCl is expected to improve the patient compliance, form better dosage regimen and provide maintenance therapy to patients suffering from inflammation and allergy. These promising results showed the feasibility of delivering Piperine HCl through transdermal matrix patch. The developed transdermal patches of Piperine HCl may prove to be a better alternative to conventional dosage forms in allergy as revealed by the results
Cite this article:
Harshal S Patil, Sourabh Jain, Karunakar Shukla, Paresh A Patil. Development and Evaluation of Transdermal patches of Piperine hydrochloride. Research Journal of Pharmaceutical Dosage Forms and Technology.2022; 14(2):133-8. doi: 10.52711/0975-4377.2022.00021
Cite(Electronic):
Harshal S Patil, Sourabh Jain, Karunakar Shukla, Paresh A Patil. Development and Evaluation of Transdermal patches of Piperine hydrochloride. Research Journal of Pharmaceutical Dosage Forms and Technology.2022; 14(2):133-8. doi: 10.52711/0975-4377.2022.00021 Available on: https://rjpdft.com/AbstractView.aspx?PID=2022-14-2-6
REFERENCES:
1. Jain N.K. (1997). Controlled and novel drug delivery, first edition, CBS Publisher and Distributors New Delhi.
2. Chien Y.W. (1992). Novel drug delivery systems, drugs and the Pharmaceutical Sciences, Vol.50, Marcel Dekkar, New York, NY;797.
3. Guy R.H. (1996). Current status and future prospects of transdermal drug delivery, Pharm Res., 13, 1765-1769.
4. Bagyalakshmi J., Vamsikrishna R.P., Manavalan R., Ravi T.K. and Manna P.K. (2007). Formulation development and in vitro and in vivo evaluation of membrane-moderated transdermal systems of ampicillin sodium in ethanol: pH 4.7 buffer solvent system. AAPS PharmSciTech, 8(1), E50-E55.
5. Shaila L., Pandey S and Udupa N. (2006). Design and evaluation of matrix controlled Transdermal drug delivery system of nicitin suitable for use in smoking cessation. Indian Journ. Pharm. Science; 68: 179-184.
6. Bernar B. and John V.A. (1994). Pharmacokinetic characterization of Transdermal delivery systems. Jour.Clinical pharmacokinetics, 26(2): 1`21-34.
7. Tsai J.C, Guy R.H, Thornfeldt C.R, Gao W.N, Feingold K.R and Elias P.M. (1998). Metabolic Approaches to Enhance Transdermal drug delivery”, Jour.Pharm. Sci.,85;643-648.
8. Williams A.C and Barry B. W. (2004). Penetration Enhancers, Adv. Drug delivery ststems, Rev, 56:603-618.
9. Pellet M., Raghavan S.L, Hadgraft J and Davis A.F. (2003). The application of supersaturated systems to percutaneous drug delivery” In: Guy R.H. andHadgraft J. Transdermal drug delivery, Marcel Dekkar Inc., New York, 2003, pp, 305-326.
10. Loyd V. Allen Jr, Nicholas G. Popovich and Howard C. Ansel (2005). Pharmaceutical dosage forms and drug delivery systems, eighth edition, Wolter Kluwer Publishers, New Delhi.
11. Nachum Z., Shupak A., Gordon C.R. (2006). Transdermal scopolamine for prevention of motion sickness: clinical pharmacokinetics and therapeutic applications. Clinical Pharmacokinetics, 45 (6): 543–66.
12. Alexander, A., Dwivedi, S., Ajazuddin, Giri, T. K., Saraf, S. and Tripathi, D. K. (2012). Approaches for breaking the barriers of drug permeation through transdermal drug delivery. Journal of Controlled Release, 164(1), 26-40.
13. Asbill, C. S. and Michniak, B. B. (2000). Percutaneous penetration enhancers: Local versus transdermal activity. Pharmaceutical Science and Technology Today, 3(1), 36-41.
14. Babu, R. J. and Pandit, J. K. (2005). Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems. International Journal of Pharmaceutics, 288(2), 325-334.
15. Barrett, C. W. (1969). Skin penetration. Journal of Society of Cosmetic Chemists, 487-499.
16. Barry, B. W. (2002). Drug delivery routes in skin: A novel approach. Advanced Drug Delivery Reviews, 54, S31-S40.
17. Barry, B. W. (2007). Transdermal drug delivery In: Aulton, M. E. (Ed). Pharmaceutics: The design and manufacturing of medicines. 3rd Edition. Churchill Livingstone, London, 2007, 565-587.
18. Benson, H. (2005). Transdermal drug delivery: Penetration enhancement techniques. Current Drug Delivery, 2(1), 23-33.
19. Brown, M. B. (2006). Dermal and transdermal drug delivery systems: Current and future prospects. Drug Delivery, 13:175-187.
20. Chen, Y., Quan, P., Liu, X., Wang, M. and Fang, L. (2014). Novel chemical permeation enhancers for transdermal drug delivery. Asian Journal of Pharmaceutical Sciences, 9(2), 51-64.
21. Chien, Y. W. (1992). Transdermal drug delivery and delivery systems. In: Novel drug delivery systems. Marcel Dekker, Inc., New York, 301-380.
22. Degim, I. T. (2006). New tools and approaches for predicting skin permeability. Drug Discovery Today, 11(12), 517-523.
23. Dhiman, S., Singh, T. G. and Rehni, A. K. (2011). Transdermal patches: A recent approach to new drug delivery system. International Journal of Pharmacy and Pharmaceutical Sciences, 3(5), 26-34.
24. Guy, R. H. and Hadgraft, J. (1987). The effect of penetration enhancers on the kinetics of percutaneous absorption. Journal of Controlled Release, 5(1), 43-51.
25. Consumer Reports (2013), Using Antihistamines to Treat Allergies, Hay Fever, & Hives - Comparing Effectiveness, Safety, and Price (PDF), Yonkers, New York: Consumer Reports.
26. Panula P, Chazot PL, Cowart M, et al. (2015). International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacol. Rev. 67 (3): 601–55.
27. Leurs R, Church MK, Taglialatela M (2002). H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clinical and Experimental Allergy. 32 (4): 489–98.
28. Norrby K (1995). Evidence of a dual role of endogenous histamine in angiogenesis. Int J Exp Pathol. 76 (2): 87–92.
29. Monroe EW, Daly AF, Shalhoub RF (1997). "Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines". The Journal of Allergy and Clinical Immunology. 99 (2): S798– 806.
30. Terland, O.; Flatmark, T. (1999). "Drug-induced parkinsonism: Cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles". Neuropharmacology. 38 (6): 879–88.